Nurix Therapeutics (NRIX) Retained Earnings (2019 - 2025)
Historic Retained Earnings for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$1.0 billion.
- Nurix Therapeutics' Retained Earnings fell 3579.7% to -$1.0 billion in Q4 2025 from the same period last year, while for Nov 2025 it was -$1.0 billion, marking a year-over-year decrease of 3579.7%. This contributed to the annual value of -$1.0 billion for FY2025, which is 3579.7% down from last year.
- As of Q4 2025, Nurix Therapeutics' Retained Earnings stood at -$1.0 billion, which was down 3579.7% from -$925.0 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Retained Earnings registered a high of -$128.0 million during Q1 2021, and its lowest value of -$1.0 billion during Q4 2025.
- Moreover, its 5-year median value for Retained Earnings was -$484.8 million (2023), whereas its average is -$508.5 million.
- As far as peak fluctuations go, Nurix Therapeutics' Retained Earnings plummeted by 11865.75% in 2021, and later tumbled by 3274.16% in 2024.
- Nurix Therapeutics' Retained Earnings (Quarter) stood at -$220.9 million in 2021, then plummeted by 81.65% to -$401.3 million in 2022, then crashed by 35.87% to -$545.2 million in 2023, then crashed by 35.5% to -$738.8 million in 2024, then crashed by 35.8% to -$1.0 billion in 2025.
- Its last three reported values are -$1.0 billion in Q4 2025, -$925.0 million for Q3 2025, and -$838.6 million during Q2 2025.